JPRN-jRCT2090220391已完成1 期
A phase I/IIa safety and efficacy study of allogeneic periodontal ligament-derived mesenchymal stromal cell sheet product (TWP-0001) in patients with periodontitis, consisting of 1 wall intrabony defect, Class III furcation defect, or horizontal defect, with probing depths of 4-9mm after the initial therapy - TWP-0001 Study
Tokyo women's medical university, institute of advanced biomedical engineering and science, and department of oral and maxillofacial surgery, Takanori Iwata0 个研究点目标入组 6 人开始时间: 2018年10月17日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 6
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 < 65age old（—）
- 性别
- All
入选标准
- •Periodontitis, consisting of 1 wall intrabony defect, Class III furcation defect, or horizontal defect, with probing depths of 4 - 9 mm after the initial therapy
排除标准
- •maxillary Class III furcation
研究者
相似试验
已完成
1 期
A phase I/IIa safety and efficacy study of allogeneic periodontal ligament-derived mesenchymal stromal cell sheet product (TWP-0001) in patients with periodontitis, consisting of 1 wall intrabony defect, Class III furcation defect, or horizontal defect, with probing depths of 4 - 9 mm after the initial therapyJPRN-UMIN000034310Tokyo Medical and Dental University6
进行中（未招募）
1 期
A prospective phase I/II study to evaluate allogeneic mesenchymal stromal cells for the treatment of skin disease in children with recessive dystrophic epidermolysis bullosa.EUCTR2012-001394-87-GBKing's College London10
招募中
1 期
Application of Cord Blood Platelet Gel (CBPG) for the treatment of non-healing skin ulcers due to the cutaneous chronic GVHDIRCT20190101042197N1Royan Stem cell Technology Co.15
招募中
1 期
Allogenic Natural Killer cell therapy in relapsed Neuroblastoma pediatric patientseuroblastoma.Malignant neoplasm of unspecified part of unspecified adrenal glandC74.90IRCT20201202049568N1Tehran University of Medical Sciences5
已完成
1 期
Evaluation of the safety and efficacy of allogenic hematopoietic stem cell transplantation (HSCT) from HLA-mismatched related donors using alemtuzumab in patients with hematological malignancies.Hematological malignanciesJPRN-C000000357GCP-ISS HE0402 group48